Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients
Feng-Ju Zhao, Qun Su, Wei Zhang, Wen-Cui Yang, Lin Zhao, Li-Ying Gao, Department of Radiotherapy, Gansu Cancer Hospital, Lanzhou 730050, Gansu Province, China
Author contributions: Zhao FJ and Su Q design the experiment; Zhang W drafted the work, Yang WC, Zhao L and Gao LY collected the data; Zhao FJ and Su Q analysed and interpreted data, Zhang W, Zhao FJ and Gao LY wrote the article.
Institutional review board statement: This study was approved by the Gansu Cancer Hospital Ethics Committee.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there is no conflict of interest between them.
Data sharing statement: No additional data are available.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Ying Gao, MD, Chief Doctor, Department of Radiotherapy, Gansu Cancer Hospital, No. 2 Xiaoxihu East Street, Qilihe District, Lanzhou 730050, Gansu Province, China. email@example.com
Received: May 18, 2021
Peer-review started: May 18, 2021
First decision: June 15, 2021
Revised: June 29, 2021
Accepted: August 3, 2021
Article in press: August 3, 2021
Published online: September 26, 2021